Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-IMG-158899

Xenbase Image ID: 158899

Figure 5: Adam13 induces pcdh8l via AP2. (A, C, D) Relative expression of AP2 and pcdh8l in naïve ectoderm (animal cap) by real-time PCR. One-cell stage embryos were injected with 1 ng of the various adam13 constructs and morpholinos and embryos were collected at stage 9 to dissect animal cap cells (AC). AC were grown in 0.5X MBS until sibling embryos reached stage 20 to 22. Messenger RNA was extracted from 10 AC for gene expression analysis. Expression was normalized using GAPDH and compared to the expression in non-injected AC (NI). (A) Real-time PCR data show that adam13 can induce AP2α by more than 4 fold. Both proteolytic activity and the presence of the cytoplasmic domain are essential for full activation. (B) Luciferase activity of AP2α promoter in Hek293T cells show induction by adam13 and ADAM19 but not ADAM9. For each transfection the Luciferase values were normalized to the Renilla values driven by the CMV promoter. In these assays, the absence of proteolytic activity (A13E/A) reduced AP2 induction only slightly, while the deletion of the cytoplasmic domain (Cyto) prevented the activity. (C) Induction of AP2by adam13 was prevented by the KD of AP2 (10 ng of MOAP2) but not -catenin (20 ng of Mo-catenin). (D) Expression of AP2 in response of adam13 also depends on AP2 but not -catenin. Error bars represent standard error to the mean (Mean± S.E.M). One-way ANOVA was performed to determine statistical significance. Statistically significant at **p < 0.01, ***p < 0.001.

Image published in: Khedgikar V et al. (2017)

© 2017, Khedgikar et al. This image is reproduced with permission of the journal and the copyright holder. This is an open-access article distributed under the terms of the Creative Commons Attribution license

Larger Image
Printer Friendly View

Return to previous page